应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01875 东曜药业—B
已收盘 03-28 16:08:03
1.650
+0.130
+8.55%
最高
1.650
最低
1.520
成交量
6.84万
今开
1.530
昨收
1.520
日振幅
8.55%
总市值
12.75亿
流通市值
12.75亿
总股本
7.73亿
成交额
10.47万
换手率
0.01%
流通股本
7.73亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
东曜药业-B盘中异动 临近收盘快速上涨5.33%
自选股智能写手 · 15:59
东曜药业-B盘中异动 临近收盘快速上涨5.33%
东曜药业-B(01875)股价上升5.263%,现价港币$1.6
阿斯达克财经 · 15:59
东曜药业-B(01875)股价上升5.263%,现价港币$1.6
东曜药业-B盘中异动 早盘快速跳水9.88%报1.550港元
自选股智能写手 · 03-26 09:42
东曜药业-B盘中异动 早盘快速跳水9.88%报1.550港元
东曜药业-B股价飙升11.95% 市值涨1.65亿港元
自选股智能写手 · 03-25
东曜药业-B股价飙升11.95% 市值涨1.65亿港元
V观财报丨东曜药业:2023年营收同比增长77%
中新经纬 · 03-19
V观财报丨东曜药业:2023年营收同比增长77%
东曜药业-B盘中异动 早盘急速拉升8.21%报1.700港元
自选股智能写手 · 03-19
东曜药业-B盘中异动 早盘急速拉升8.21%报1.700港元
东曜药业-B盘中异动 下午盘大幅下跌5.78%报1.630港元
自选股智能写手 · 03-18
东曜药业-B盘中异动 下午盘大幅下跌5.78%报1.630港元
智通港股早知道 | 工信部将研究制定汽车以旧换新、充换电基础设施建设等支持政策 央行:前两月社融增量8.06万亿
智通财经 · 03-18
智通港股早知道 | 工信部将研究制定汽车以旧换新、充换电基础设施建设等支持政策 央行:前两月社融增量8.06万亿
《公司业绩》东曜药业(01875.HK)全年亏损收窄至3,776万人民币
阿斯达克财经 · 03-17
《公司业绩》东曜药业(01875.HK)全年亏损收窄至3,776万人民币
东曜药业2023年实现营收7.81亿元 同比增长77% 盈利能力持续提升
金融界 · 03-16
东曜药业2023年实现营收7.81亿元 同比增长77% 盈利能力持续提升
东曜药业-B(01875)营收增长77%,CDMO业务同比增94%
和讯网 · 03-15
东曜药业-B(01875)营收增长77%,CDMO业务同比增94%
东曜药业-B(01875.HK)公布年度业绩 收入大幅增长77% 集团造血能力持续增强
格隆汇资讯 · 03-15
东曜药业-B(01875.HK)公布年度业绩 收入大幅增长77% 集团造血能力持续增强
东曜药业-B(01875)2023年实现营收7.81亿元 同比增长77% 盈利能力持续提升
智通财经 · 03-15
东曜药业-B(01875)2023年实现营收7.81亿元 同比增长77% 盈利能力持续提升
东曜药业-B盘中异动 下午盘股价大涨8.68%报1.740港元
自选股智能写手 · 03-15
东曜药业-B盘中异动 下午盘股价大涨8.68%报1.740港元
东曜药业-B盘中异动 下午盘股价大跌7.93%报1.510港元
自选股智能写手 · 03-14
东曜药业-B盘中异动 下午盘股价大跌7.93%报1.510港元
东曜药业-B(01875)股价下跌7.927%,现价港币$1.51
阿斯达克财经 · 03-14
东曜药业-B(01875)股价下跌7.927%,现价港币$1.51
东曜药业-B股价重挫11.18% 市值跌1.3亿港元
自选股智能写手 · 03-12
东曜药业-B股价重挫11.18% 市值跌1.3亿港元
东曜药业-B股价飙升12.67% 市值涨1.65亿港元
自选股智能写手 · 03-11
东曜药业-B股价飙升12.67% 市值涨1.65亿港元
东曜药业-B(01875.HK)拟3月15日举行董事会会议批准年度业绩
格隆汇资讯 · 03-05
东曜药业-B(01875.HK)拟3月15日举行董事会会议批准年度业绩
东曜药业-B盘中异动 快速跳水5.09%报1.510港元
自选股智能写手 · 03-04
东曜药业-B盘中异动 快速跳水5.09%报1.510港元
加载更多
公司概况
公司名称:
东曜药业—B
所属市场:
SEHK
上市日期:
--
主营业务:
东曜药业于2019年在香港联交所主板上市,2021年全面转型,致力于成为全球药物开发领域专业CDMO合作伙伴,提供生物药开发到生产一站式解决方案。 公司拥有从研发、工艺开发、临床试验、注册报批到商业化生产的全流程经验,建立了完整的ADC技术平台,具备核心偶联工艺和放大的技术优势,以及ADC关键质量属性的自主分析能力,保证产品高质量开发。
发行价格:
--
{"stockData":{"symbol":"01875","market":"HK","secType":"STK","nameCN":"东曜药业—B","latestPrice":1.65,"timestamp":1711613283013,"preClose":1.52,"halted":0,"volume":68400,"delay":0,"floatShares":772787887,"shares":772787887,"eps":-0.056088917,"marketStatus":"已收盘","marketStatusCode":5,"change":0.13,"latestTime":"03-28 16:08:03","open":1.53,"high":1.65,"low":1.52,"amount":104656,"amplitude":0.085526,"askPrice":1.65,"askSize":5600,"bidPrice":1.5,"bidSize":800,"shortable":0,"etf":0,"ttmEps":-0.056088916042002473,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1712021400000},"adr":0,"listingDate":1573142400000,"adjPreClose":1.52,"openAndCloseTimeList":[[1711589400000,1711598400000],[1711602000000,1711612800000]],"volumeRatio":7.702703,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01875","defaultTab":"news","newsList":[{"id":"2422913028","title":"东曜药业-B盘中异动 临近收盘快速上涨5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422913028","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422913028?lang=zh_cn&edition=full","pubTime":"2024-03-28 15:59","pubTimestamp":1711612764,"startTime":"0","endTime":"0","summary":"2024年03月28日临近收盘15时59分,东曜药业-B股票出现波动,股价大幅上涨5.33%。截至发稿,该股报1.601港元/股,成交量6.8万股,换手率0.01%,振幅5.26%。东曜药业-B股票所在的生物技术行业中,整体涨幅为1.07%。东曜药业-B公司简介:东曜药业股份有限公司是一家主要从事开发及商业化肿瘤药物及疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281559247a4fb808&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281559247a4fb808&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422113006","title":"东曜药业-B(01875)股价上升5.263%,现价港币$1.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2422113006","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422113006?lang=zh_cn&edition=full","pubTime":"2024-03-28 15:59","pubTimestamp":1711612740,"startTime":"0","endTime":"0","summary":"[上升股]东曜药业-B(01875) 股价在下午03:59比前收市价上升5.263%,现股价为港币$1.6。至目前为止,今日最高价为$1.6,而最低价为$1.52。总成交量为6.52万股,总成交金额为港币$9.962万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2403284905/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2422268849","title":"东曜药业-B盘中异动 早盘快速跳水9.88%报1.550港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422268849","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422268849?lang=zh_cn&edition=full","pubTime":"2024-03-26 09:42","pubTimestamp":1711417323,"startTime":"0","endTime":"0","summary":"2024年03月26日早盘09时42分,东曜药业-B股票出现异动,股价快速跳水9.88%。截至发稿,该股报1.550港元/股,成交量1200股,换手率0.00%,振幅0.00%。东曜药业-B股票所在的生物技术行业中,整体涨幅为0.17%。其相关个股中,巨子生物、荃信生物-B、中国抗体-B涨幅较大,振幅较大的相关个股有博安生物、科笛-B、欧康维视生物-B,振幅分别为4.58%、4.19%、4.03%。东曜药业-B公司简介:东曜药业股份有限公司是一家主要从事开发及商业化肿瘤药物及疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260942037a4f05a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260942037a4f05a0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422659533","title":"东曜药业-B股价飙升11.95% 市值涨1.65亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422659533","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422659533?lang=zh_cn&edition=full","pubTime":"2024-03-25 09:35","pubTimestamp":1711330517,"startTime":"0","endTime":"0","summary":"2024年03月25日早盘09时35分,东曜药业-B股票出现异动,股价大幅拉升11.95%。截至发稿,该股报1.770港元/股,成交量4000股,换手率0.00%,振幅0.00%。东曜药业-B股票所在的生物技术行业中,整体涨幅为0.31%。其相关个股中,东曜药业-B、药明巨诺-B、药明合联涨幅较大,振幅较大的相关个股有圣诺医药-B、北海康成-B、药明巨诺-B,振幅分别为6.02%、4.92%、4.76%。东曜药业-B公司简介:东曜药业股份有限公司是一家主要从事开发及商业化肿瘤药物及疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240325093517791c7daa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240325093517791c7daa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420215931","title":"V观财报丨东曜药业:2023年营收同比增长77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420215931","media":"中新经纬","top":-1,"share":"https://www.laohu8.com/m/news/2420215931?lang=zh_cn&edition=full","pubTime":"2024-03-19 14:39","pubTimestamp":1710830379,"startTime":"0","endTime":"0","summary":"东曜药业在港交所发布2023年全年业绩公告,营业收入为7.8亿元,同比增长77%。其中,产品销售收入为6.3亿元,同比增长107%,主要贡献来自于核心产品朴欣汀(贝伐珠单抗注射液)销售业绩的增长。全年净亏损为3775.7万元,较2022年度亏损额减少1228.9万元,收窄25%。(中新经纬APP)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403191546327a4d9b37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403191546327a4d9b37&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420268829","title":"东曜药业-B盘中异动 早盘急速拉升8.21%报1.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420268829","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420268829?lang=zh_cn&edition=full","pubTime":"2024-03-19 09:51","pubTimestamp":1710813106,"startTime":"0","endTime":"0","summary":"2024年03月19日早盘09时51分,东曜药业-B股票出现异动,股价急速上涨8.21%。截至发稿,该股报1.700港元/股,成交量2万股,换手率0.00%,振幅0.00%。资金方面,该股资金流入0港元,流出0港元。东曜药业-B股票所在的生物技术行业中,整体跌幅为0.68%。该信息摘要如下:东曜药业公布2023年业绩,该集团营业收入为约人民币7.81亿元,同比增长77%。因2023年全年无一次性授权金收入,剔除该因素影响,2023年全年收入同比增长达101%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240319095147861df40f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240319095147861df40f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420737416","title":"东曜药业-B盘中异动 下午盘大幅下跌5.78%报1.630港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420737416","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420737416?lang=zh_cn&edition=full","pubTime":"2024-03-18 13:22","pubTimestamp":1710739369,"startTime":"0","endTime":"0","summary":"2024年03月18日下午盘13时22分,东曜药业-B股票出现异动,股价急速跳水5.78%。截至发稿,该股报1.630港元/股,成交量1.28万股,换手率0.00%,振幅0.58%。东曜药业-B股票所在的生物技术行业中,整体跌幅为0.18%。该信息摘要如下:东曜药业-B2023年营收达7.81亿元,同比增长77%,盈利能力显著提升。东曜药业-B发布的2023年业绩显示,营业收入约为7.81亿元人民币,同比大幅增长77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240318132249861defa6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240318132249861defa6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420465380","title":"智通港股早知道 | 工信部将研究制定汽车以旧换新、充换电基础设施建设等支持政策 央行:前两月社融增量8.06万亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2420465380","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2420465380?lang=zh_cn&edition=full","pubTime":"2024-03-18 07:38","pubTimestamp":1710718696,"startTime":"0","endTime":"0","summary":"同时结合2024消费促进年工作安排,组织开展全国汽车换新消费季活动,调动各方力量参与,扩大政策的影响力。央行:前两月新增信贷6.37万亿 社融增量8.06万亿 M2增长8.7%2月末,广义货币余额299.56万亿元,同比增长8.7%。前两个月净投放现金7566亿元。前两个月人民币贷款增加6.37万亿元。初步统计,2024年前两个月社会融资规模增量累计为8.06万亿元,比上年同期少1.1万亿元。CDMO/CMO业务收入人民币1.41亿元,同比增长94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1087516.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420480604","title":"《公司业绩》东曜药业(01875.HK)全年亏损收窄至3,776万人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2420480604","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2420480604?lang=zh_cn&edition=full","pubTime":"2024-03-17 21:12","pubTimestamp":1710681120,"startTime":"0","endTime":"0","summary":"东曜药业-B(01875.HK) 公布2023年止年度业绩,收益录得7.81亿人民币(下同),按年增加76.5%。亏损由上年度4,992万元,收窄至3,776万元,每股亏损5分。不派末期息。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2023/08/11中期业绩无派息2023/03/23末期业绩无派息 2022/08/12中期业绩无派息 2022/03/24末期业绩无派息 AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220720120853018_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220720120853018_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1333981/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2419584891","title":"东曜药业2023年实现营收7.81亿元 同比增长77% 盈利能力持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2419584891","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419584891?lang=zh_cn&edition=full","pubTime":"2024-03-16 08:34","pubTimestamp":1710549263,"startTime":"0","endTime":"0","summary":"东曜药业公布2023年业绩,该集团营业收入为约人民币7.81亿元,同比增长77%。其中,产品销售收入为人民币6.3亿元,同比增长107%,这主要贡献来自于核心产品朴欣汀(贝伐珠单抗注射液)销售业绩的大幅增长。CDMO/CMO业务收入人民币1.41亿元,同比增长94%。因2023年全年无一次性授权金收入(2022年全年为人民币5415.1万元),剔除该因素影响,2023年全年收入同比增长达101%。该集团造血能力持续增强,经营活动现金净流量人民币5643.1万元,持续正向。盈利能力持续提升,经调整后税息折旧及摊销前利润(EBITDA)人民币4004.1万元,同比增长274%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403160840528788ea41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403160840528788ea41&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419016339","title":"东曜药业-B(01875)营收增长77%,CDMO业务同比增94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419016339","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2419016339?lang=zh_cn&edition=full","pubTime":"2024-03-15 23:09","pubTimestamp":1710515362,"startTime":"0","endTime":"0","summary":"快讯正文东曜药业-B2023年营收达7.81亿元,同比增长77%,盈利能力显著提升。东曜药业-B发布的2023年业绩显示,营业收入约为7.81亿元人民币,同比大幅增长77%。此外,CDMO/CMO业务收入也实现了1.41亿元,同比增长94%。东曜药业已建立起集抗体、ADC原液和制剂于一体的商业化生产平台。CDMO业务增长迅速,全年新增项目39个,同比增长44%,累计至95个项目。东曜药业的生物药CDMO总体规模位居国内前列,是国内具备商业化生产能力的一站式ADC CDMO。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403160002288b383179&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403160002288b383179&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419903308","title":"东曜药业-B(01875.HK)公布年度业绩 收入大幅增长77% 集团造血能力持续增强","url":"https://stock-news.laohu8.com/highlight/detail?id=2419903308","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2419903308?lang=zh_cn&edition=full","pubTime":"2024-03-15 22:28","pubTimestamp":1710512903,"startTime":"0","endTime":"0","summary":"格隆汇3月15日丨东曜药业-B宣布,2023年,集团营业收入为人民币780,629千元,同比增长77%。CDMO/CMO业务收入人民币140,898千元,同比增长94%。因2023年全年无一次性授权金收入,剔除该因素影响,2023年全年收入同比增长达101%。集团造血能力持续增强,经营活动现金净流量人民币56,431千元,持续正向。通过CDMO及已上市产品商业化销售等多元化收入模式,持续为股东创造价值,为人类健康事业贡献力量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403152228298b37e545&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403152228298b37e545&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419970730","title":"东曜药业-B(01875)2023年实现营收7.81亿元 同比增长77% 盈利能力持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2419970730","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2419970730?lang=zh_cn&edition=full","pubTime":"2024-03-15 22:21","pubTimestamp":1710512514,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东曜药业-B 公布2023年业绩,该集团营业收入为约人民币7.81亿元,同比增长77%。CDMO/CMO业务收入人民币1.41亿元,同比增长94%。因2023年全年无一次性授权金收入,剔除该因素影响,2023年全年收入同比增长达101%。盈利能力持续提升,经调整后税息折旧及摊销前利润人民币4004.1万元,同比增长274%。CDMO业务增速高于行业平均,呈现强劲发展趋势,全年新增项目39个,同比增长44%,累计至95个项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1087386.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419911973","title":"东曜药业-B盘中异动 下午盘股价大涨8.68%报1.740港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419911973","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419911973?lang=zh_cn&edition=full","pubTime":"2024-03-15 14:20","pubTimestamp":1710483606,"startTime":"0","endTime":"0","summary":"2024年03月15日下午盘14时20分,东曜药业-B股票出现异动,股价快速拉升8.68%。截至发稿,该股报1.740港元/股,成交量2400股,换手率0.00%,振幅0.00%。资金方面,该股资金流入0港元,流出0港元。东曜药业-B股票所在的生物技术行业中,整体跌幅为1.51%。东曜药业-B公司简介:东曜药业股份有限公司是一家主要从事开发及商业化肿瘤药物及疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031514200687e7940a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031514200687e7940a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419647943","title":"东曜药业-B盘中异动 下午盘股价大跌7.93%报1.510港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2419647943","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419647943?lang=zh_cn&edition=full","pubTime":"2024-03-14 15:00","pubTimestamp":1710399620,"startTime":"0","endTime":"0","summary":"2024年03月14日下午盘15时00分,东曜药业-B股票出现异动,股价快速下挫7.93%。截至发稿,该股报1.510港元/股,成交量2.48万股,换手率0.00%,振幅7.93%。资金方面,该股资金流入2.0992万港元,流出1.812万港元。东曜药业-B股票所在的生物技术行业中,整体跌幅为0.04%。东曜药业-B公司简介:东曜药业股份有限公司是一家主要从事开发及商业化肿瘤药物及疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031415002187e78e49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031415002187e78e49&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419076647","title":"东曜药业-B(01875)股价下跌7.927%,现价港币$1.51","url":"https://stock-news.laohu8.com/highlight/detail?id=2419076647","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2419076647?lang=zh_cn&edition=full","pubTime":"2024-03-14 15:00","pubTimestamp":1710399600,"startTime":"0","endTime":"0","summary":"[下跌股]东曜药业-B(01875) 股价在下午03:00比前收市价下跌7.927%,现股价为港币$1.51。至目前为止,今日最高价为$1.64,而最低价为$1.51。总成交量为2.48万股,总成交金额为港币$3.911万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2403141679/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2418322637","title":"东曜药业-B股价重挫11.18% 市值跌1.3亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2418322637","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418322637?lang=zh_cn&edition=full","pubTime":"2024-03-12 11:11","pubTimestamp":1710213096,"startTime":"0","endTime":"0","summary":"2024年03月12日早盘11时11分,东曜药业-B股票出现异动,股价快速下挫11.18%。截至发稿,该股报1.510港元/股,成交量400股,换手率0.00%,振幅0.00%。东曜药业-B股票所在的生物技术行业中,整体涨幅为1.32%。东曜药业-B公司简介:东曜药业股份有限公司是一家主要从事开发及商业化肿瘤药物及疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403121111367a4bca54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403121111367a4bca54&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418155875","title":"东曜药业-B股价飙升12.67% 市值涨1.65亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2418155875","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418155875?lang=zh_cn&edition=full","pubTime":"2024-03-11 09:51","pubTimestamp":1710121916,"startTime":"0","endTime":"0","summary":"2024年03月11日早盘09时51分,东曜药业-B股票出现异动,股价快速拉升12.67%。截至发稿,该股报1.690港元/股,成交量400股,换手率0.00%,振幅0.00%。资金方面,该股资金流入676港元,流出0港元。东曜药业-B股票所在的生物技术行业中,整体跌幅为0.06%。东曜药业-B公司简介:东曜药业股份有限公司是一家主要从事开发及商业化肿瘤药物及疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031109515687e77876&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031109515687e77876&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417469835","title":"东曜药业-B(01875.HK)拟3月15日举行董事会会议批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2417469835","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2417469835?lang=zh_cn&edition=full","pubTime":"2024-03-05 16:46","pubTimestamp":1709628411,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨东曜药业-B(01875.HK)发布公告,公司谨定于2024年3月15日(星期五)举行董事会会议,以考虑及通过集团截至2023年12月31日止年度的全年业绩,以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403051646578b073c30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403051646578b073c30&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416019847","title":"东曜药业-B盘中异动 快速跳水5.09%报1.510港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2416019847","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416019847?lang=zh_cn&edition=full","pubTime":"2024-03-04 15:51","pubTimestamp":1709538665,"startTime":"0","endTime":"0","summary":"2024年03月04日临近收盘15时51分,东曜药业-B股票出现异动,股价快速下跌5.09%。截至发稿,该股报1.510港元/股,成交量16.84万股,换手率0.02%,振幅5.66%。东曜药业-B股票所在的生物技术行业中,整体涨幅为2.91%。东曜药业-B公司简介:东曜药业股份有限公司是一家主要从事开发及商业化肿瘤药物及疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403041551057a4930b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403041551057a4930b8&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.totbiopharm.com.cn","stockEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":-0.0788},{"period":"3month","weight":-0.1958},{"period":"6month","weight":-0.2323},{"period":"1year","weight":-0.2512},{"period":"ytd","weight":-0.2284}],"compareEarnings":[{"period":"1week","weight":-0.0091},{"period":"1month","weight":-0.0145},{"period":"3month","weight":-0.0382},{"period":"6month","weight":-0.0796},{"period":"1year","weight":-0.1714},{"period":"ytd","weight":-0.0384}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"东曜药业于2019年在香港联交所主板上市,2021年全面转型,致力于成为全球药物开发领域专业CDMO合作伙伴,提供生物药开发到生产一站式解决方案。\n公司拥有从研发、工艺开发、临床试验、注册报批到商业化生产的全流程经验,建立了完整的ADC技术平台,具备核心偶联工艺和放大的技术优势,以及ADC关键质量属性的自主分析能力,保证产品高质量开发。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.091467},{"month":2,"riseRate":0,"avgChangeRate":-0.040488},{"month":3,"riseRate":0.2,"avgChangeRate":-0.062317},{"month":4,"riseRate":1,"avgChangeRate":0.101664},{"month":5,"riseRate":0.5,"avgChangeRate":0.047385},{"month":6,"riseRate":0.5,"avgChangeRate":-0.00824},{"month":7,"riseRate":0.25,"avgChangeRate":-0.016973},{"month":8,"riseRate":0.25,"avgChangeRate":-0.044118},{"month":9,"riseRate":0.5,"avgChangeRate":0.010086},{"month":10,"riseRate":0.5,"avgChangeRate":-0.024798},{"month":11,"riseRate":0,"avgChangeRate":-0.058082},{"month":12,"riseRate":0.8,"avgChangeRate":-0.016555}],"exchange":"SEHK","name":"东曜药业—B","nameEN":"TOT BIOPHARM-B"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东曜药业—B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东曜药业—B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东曜药业—B,01875,东曜药业—B股票,东曜药业—B股票老虎,东曜药业—B股票老虎国际,东曜药业—B行情,东曜药业—B股票行情,东曜药业—B股价,东曜药业—B股市,东曜药业—B股票价格,东曜药业—B股票交易,东曜药业—B股票购买,东曜药业—B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东曜药业—B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东曜药业—B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}